Apixaban for Cancer-Associated Venous Thromboembolism

This presentation covers the management of venous thromboembolism (VTE) in cancer patients, focusing on Apixaban versus Dalteparin. It explores trial methods, efficacy, safety findings, and clinical implications, highlighting Apixaban's potential for improving treatment adherence and patient outcomes. Conclusions emphasize its noninferiority, safety, and utility, supported by a balanced discussion of study strengths, weaknesses, and financial disclosures.